TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05071703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trilaciclib
Description: * Carboplatin combined with Etoposide (ES-SCLC patients)~* plus Topotecan (second/third line ES-SCLC patients)
Study: NCT05361044

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood samples Donnor
Description: Additional samples will be preleved in the Normothermic Regional Reperfusion at 30 min, and blood sample will be collected at the end of the Normothermic Regional Reperfusion (4 samples of 5ml).
Study: NCT05897892

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Clinical study on the mangrove sword bean food bar effect for older people
Description: The treatment group consumed 50 g mangrove sword bean food bar each day during 15 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Clinical study on the mangrove sword bean food bar effect for older people
Description: The treatment group consumed 50 g mangrove sword bean food bar each day during 15 days.
Study: NCT05181124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: coadministration of JP-1366 and aceclofenac
Description: An open-label, multiple-dosing, fixed sequence, 3-period design

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: coadministration of JP-1366 and meloxicam
Description: An open-label, multiple-dosing, fixed sequence, 3-period design

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: coadministration of JP-1366 and naproxen
Description: An open-label, multiple-dosing, fixed sequence, 3-period design

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: single-dosing of JP-1366 in Korean and Caucasian
Description: An open-label, single-dosing, parallel design
Study: NCT05325346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VLX-1005
Description: Measurement and comparison of the effects and potential interactions between VLX-1005 and argatroban on safety, tolerability, PK and PD

Intervention type: DRUG
Group type: OTHER
Intervention: VLX-1005
Description: Measurement and comparison of the effects and potential interactions between VLX-1005 and argatroban on safety, tolerability, PK and PD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Argatroban
Description: Measurement and comparison of the effects and potential interactions between VLX-1005 and argatroban on safety, tolerability, PK and PD

Intervention type: DRUG
Group type: OTHER
Intervention: Argatroban
Description: Measurement and comparison of the effects and potential interactions between VLX-1005 and argatroban on safety, tolerability, PK and PD
Study: NCT06435923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-darigabat
Description: Oral capsule
Study: NCT04920383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALPN-202
Description: Various doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab KEYTRUDA®
Description: Varies
Study: NCT05280600

Intervention type: OTHER
Intervention: Not applicable - non-interventional study
Description: Not applicable - non-interventional study

Intervention type: OTHER
Intervention: Not applicable - non-interventional study
Description: Not applicable - non-interventional study

Intervention type: OTHER
Intervention: Not applicable - non-interventional study
Description: Not applicable - non-interventional study
Study: NCT05029102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS 102
Description: 35 mg/m2，per oral，twice daily, days 1-5 and 8-12 of each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: 10mg，per oral，once daily，days 1-14 of each 21-day cycle
Study: NCT05604781

Intervention type: DEVICE
Intervention: Symfony & Synergy IOL combination
Description: The Symfony IOL will be implanted in the dominant eye while the Synergy IOL will be implanted in the non-dominant eye.
Study: NCT05203783

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kinesio Tape Application
Description: Kinesio Tape (KT) application: Participants in the experimental group received additional taping using KT by an experience therapist with prior training in KT application. The tape was applied using the method proposed for the sacrospinalis muscle (Kase, 1996). Y-shaped tape was applied as shown in Figure 1. While the participant was in standing position, the origin of the Y-shaped tape was attached over the centre of the sacrum without stretching the tape and afterward subjects gradually bent forward. A 5-degree angle was maintained within the valley of the Y tape. The tape was changed on the fourth day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio Tape Application
Description: Kinesio Tape (KT) application: Participants in the experimental group received additional taping using KT by an experience therapist with prior training in KT application. The tape was applied using the method proposed for the sacrospinalis muscle (Kase, 1996). Y-shaped tape was applied as shown in Figure 1. While the participant was in standing position, the origin of the Y-shaped tape was attached over the centre of the sacrum without stretching the tape and afterward subjects gradually bent forward. A 5-degree angle was maintained within the valley of the Y tape. The tape was changed on the fourth day
Study: NCT04722731

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Confident Parents - Brave Children (CPBT)
Description: Session 1: Psychoeducation.~Session 2: How to decrease criticism and rejection. Skills that provide a warm parenting style and acceptance of the child: validation and child directed play/activities.~Session 3: Strategies to increase the autonomy of the child. The parents will learn how to use a stepladder approach to decrease overprotective behaviours.~Session 4: How to decrease modelling of anxious behaviours and how to be a brave role model.~Session 5: How to recognise and respond when your child is anxious. How to help your child approach new or scary things by using a stepladder approach.~Session 6: Review of the principles and skills learned during the program. The group members will make a plan for how to continue the work on their own.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-help book What all parents ought to know
Description: Participants in the control group will receive a self-help parenting book containing general research-based parenting strategies. They will be instructed to read the book within the 10 weeks from baseline to post.
Study: NCT05403502

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: t:slim X2 insulin pump with Control-IQ technology 1.5
Description: t:slim X2 insulin pump with Control-IQ technology 1.5, and wearing the Dexcom G6 sensor, used with Lyumjev® insulin.
Study: NCT04745052

Intervention type: OTHER
Intervention: Clinical observation index
Description: The first is to verify the application effect of intravenous thrombolytic hemorrhage prediction models (HAT, SIT-sICH, THRIVE) in the population of acute ischemic stroke in Guangdong Province, and verify the clinical application effects of existing prediction models. Secondly, analyze the predictive value of clinical indicators, optimize HAT, SIT-sICH, and THRIVE scores, construct an improved HT prediction model, and optimize and improve the existing prediction model. The third is to apply the improved HT prediction model to the clinic, collect clinical data prospectively, evaluate the prediction effect of the model, and evaluate the clinical application effect of the improved prediction model.
Study: NCT05624918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: 125 mg/m\^2 IV over 30 minutes or per site standard on days 1, 8, and 15 of a 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m\^2 IV over 30 minutes or per site standard on days 1, 8, and 15 of a 28 day cycle
Study: NCT05960396

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet intervention
Description: investigators use different diet intervention to observe the changes of biochemical indicators, body composition, Gut microbiota, metabonomics, etc. for patients with MAFLD during different periods

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet intervention
Description: investigators use different diet intervention to observe the changes of biochemical indicators, body composition, Gut microbiota, metabonomics, etc. for patients with MAFLD during different periods
Study: NCT04999046

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NaviFUS System
Description: FUS treatment will be conducted with following exposure parameters: intracranial spatial-peak temporal-average intensity (ISPTA) ceiling level: 2.8 W/cm2 (the focused ultrasound intensity in brain area considering transcranial attenuation), burst length: 3 ms, duration: three consecutive 5-minute FUS exposures with two 5-minute intermission intervals.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: NaviFUS System
Description: FUS treatment will be conducted with following exposure parameters: intracranial spatial-peak temporal-average intensity (ISPTA) ceiling level: 2.8 W/cm2 (the focused ultrasound intensity in brain area considering transcranial attenuation), burst length: 3 ms, duration: three consecutive 5-minute FUS exposures with two 5-minute intermission intervals.
Study: NCT04915404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berubicin Hydrochloride
Description: Berubicin intravenously infused will be administered at a dose of 7.1 mg/m2 as free base (equivalent to 7.5 mg/m2 Berubicin HCl) as a 2-hour intravenous (IV) infusion once daily for 3 consecutive days followed by 18 days off study drug (each cycle = 21 days).
Study: NCT06063486

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Curcumin/ Demethoxycurcumin/Bisdemethoxycurcumin-containing Supplement
Description: Given PO

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Piperine Extract (Standardized)
Description: Given PO

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT04060407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD24Fc
Description: CD24Fc will be administrated as IV infusion in a dose of 480 mg, q3w x 4, then q4w for up to 6 times.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab will be administrated as IV infusion, q3w x 4. For metastatic melanoma, the dose will be 3mg/kg, q3w x4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be administrated as IV infusion. For metastatic melanoma, the dose will be 1mg/kg, q3w x 4, then 480 mg, q4w for up to 1 year.
Study: NCT05929872

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-invasive brain stimulation
Description: ACTIVE transcranial direct current stimulation( tDCS)
Study: NCT02801318

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Polysomnography
Study: NCT04935021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATTR-CM
Description: Current treatment
Study: NCT05326503

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Meal matrix with polyphenol supplement (PPS)
Description: Test meal with polyphenol supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Meal matrix with placebo
Description: Test meal with placebo (maltodextrin) supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: No meal matrix with PPS
Description: Test drink with polyphenol supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: No meal matrix with placebo
Description: Test drink with placebo (maltodextrin) supplement
Study: NCT05453942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR441566
Description: Repeated dose of SAR441566 administered twice a day (BID) for 4 weeks under fed conditions

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Repeated dose of matching placebo administered twice a day (BID) for 4 weeks under fed condition
Study: NCT05624918

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NovoTTF-200T(P)
Description: Worn \> 18 hr /day starting C1D1 until completion of cycle 3
Study: NCT05929872

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham non-invasive brain stimulation
Description: SHAM tDCS
Study: NCT06019715

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Postpartum Remote Physical Activity Intervention
Description: Includes 8 remote health coaching session to promote physical activity, use of a Fitbit device, and use of a home based blood pressure monitor.
Study: NCT05985525

Intervention type: DEVICE
Intervention: Skeletal muscle and cerebral NIRS (research device)
Description: NIRS applied on skeletal muscle and brain on days 1, 3, and 8 of ICU admission. Monitoring applied for up to 24hrs on each day.
Study: NCT05492552

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active-at-home-HF
Description: Increase daily step count by 2,000 and weekly telephone calls.
Study: NCT05300126

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnosis
Description: Four sessions of 15 minute hypnosis, based on standardised script, focused on symptom management for the patients and of resource development for relatives.
Study: NCT05020470

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Auricular Point Acupressure (APA)
Description: Participants will learn how to self-administer APA by themselves.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Auricular Point Acupressure (APA)
Description: Participants will learn how to self-administer APA by themselves.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: In-Person Training
Description: Participants will receive in-person training to self-administer APA.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants will continue to do whatever they are instructed by theirs physicians.
Study: NCT05331326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC48-ADC
Description: RC48-ADC 2.0mg / kg, intravenous drip, once every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC48-ADC
Description: RC48-ADC 2.0mg / kg, intravenous drip, once every 2 weeks
Study: NCT05113186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib Pill
Description: The design of study is summarized as follows:~* Neoadjuvant phase with lenvatinib for 21 days (rationale: compromise between expected benefit and acceptable tolerance without compromising ablation procedure)~* PA of HCC in a curative intent (radiofrequency, microwave or electroporation)~* Adjuvant phase with lenvatinib for 3 months (rationale: compromise between expected benefit and acceptable tolerance without compromising ablation procedure)
Study: NCT05886374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMPL-415S1
Description: HMPL-415S1 will be supplied as 0.5 mg, 5 mg and 25 mg capsules
Study: NCT06471686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acamprosate
Description: 2 pills three times a day
Study: NCT06051461

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral lipid emulsions
Description: The oral lipid emulsions will contain water, sucrose, emulsifier, flavouring, and the corresponding fat (50 g/m2 of body surface area): milk cream (SFAs) or refined olive oil (MUFAs) with or without a dose of omega-3 PUFA, which will consist of 920 mg of EPA and 760 mg of DHA (ω3-LCPUFAs).

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oral lipid emulsions
Description: The oral lipid emulsions will contain water, sucrose, emulsifier, flavouring, and the corresponding fat (50 g/m2 of body surface area): milk cream (SFAs) or refined olive oil (MUFAs) with or without a dose of omega-3 PUFA, which will consist of 920 mg of EPA and 760 mg of DHA (ω3-LCPUFAs).
Study: NCT04594616

Intervention type: DEVICE
Group type: OTHER
Intervention: Smartphone-delivered CBT for MDD
Description: 8-week Smartphone-delivered CBT for MDD. In-person cognitive-behavioral therapy (CBT) is an empirically supported treatment for MDD. The app-delivered CBT in this project includes modules such as cognitive skills (e.g., cognitive restructuring, core belief work), behavioral activation, and perceptual retraining/mindfulness skills.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartphone-delivered CBT for MDD
Description: 8-week Smartphone-delivered CBT for MDD. In-person cognitive-behavioral therapy (CBT) is an empirically supported treatment for MDD. The app-delivered CBT in this project includes modules such as cognitive skills (e.g., cognitive restructuring, core belief work), behavioral activation, and perceptual retraining/mindfulness skills.
Study: NCT06231186

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: iHD-SRT
Description: received isotoxic individualized fSRT, with BED 10\>50Gy and \<100Gy, and strict OAR limits
Study: NCT04761770

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Geriatric assessment (GA) pre-transplant
Description: Assessment of comorbidities, polypharmacy, and functional, nutritional, and psychosocial impairment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: conditioning regimen
Description: Based on the Geriatric assessment.~1. HCT-CI/Age ≤4 AND no IADL impairment (less vulnerable/fit) -\> Myeloablative (MA) regimen~2. HCT-CI/Age \>4 AND/OR any IADL impairment (more vulnerable) -\> Reduced-intensity (RIC)/Nonmyeloablative (NMA) regimen

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic CD34+ selected stem cells
Description: Stem cells are collected as per institutional guidelines. CD34+ enriched stem cells will be obtained using the FDA approved reagents from Miltenyi, according to the instruction manual.
Study: NCT06114927

Intervention type: BEHAVIORAL
Intervention: Validation of a questionnaire
Description: The Conceptualization of Pain Questionnaire (COPAQ-S) Spanish version consist of 15 items and asks respondents to respond if they believe the items/statements to be true or false, although they are allowed to respond undecided. A score of 0 is given to incorrect responses and those marked as undecided; the sum of all the correct answers gives the total score. The higher the score, the better the participant understands the concept of pain.
Study: NCT05728398

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Music
Description: Music played within the fluoroscopy suite during an interventional radiology procedure.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: No Music
Description: No music played within the fluoroscopy suite during an interventional radiology procedure.
Study: NCT05591391

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mallya cap
Description: After Mallya cap is correctly attached to the insulin pen, it will automatically record treatment information (dose, time and date of injection) and send in real time to the Health2Sync's platform by Bluetooth transmission. Suggestions regarding dose titration and glycemic control will be communicated on the Health2Sync's platform.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Suggestions regarding dose titration and glycemic control will be communicated by weekly telephone calls.
Study: NCT05015569

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: COVR Medical Garment
Description: COVR undergarments are available in a Half Short design for unilateral lower extremity procedures and a Bilateral (brief) style garment designed for bilateral lower extremity procedures. Either style may be worn for upper extremity, trunk, spine procedures, etc. where an undergarment would be preferred along with a standard hospital gown. The garments are available in a variety of sizes. The COVR garments can be released at the hip(s)/waistline for improved access to the lateral hip and include retractable panels for procedural access to the groin and genitals if needed by the care team.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Patient Gown
Description: The standard patient gown is provided to all patients in a hospital setting.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Patient Gown
Description: The standard patient gown is provided to all patients in a hospital setting.
Study: NCT05030350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH94B
Description: Nasal spray
Study: NCT05448482

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transobturator tape
Description: Mid urethral sling for treatment of female stress urinary incontinence

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transobturator tape
Description: Mid urethral sling for treatment of female stress urinary incontinence
Study: NCT04802265

Intervention type: PROCEDURE
Intervention: Epiretinal membrane surgery
Description: The surgery consists of a 23 or 25-gauge pars plana vitrectomy (PPV). The surgery was performed peri-bulbar anesthesia and could be combined with phacoemulsification.~An intraocular dye is used to well visualized and facilitate ERM peeling. The ILM is not actively peeled. A search for iatrogenic breaks is performed towards the end of the procedure. Areas suspicious for breaks are treated with cryotherapy or peripheral endolaser.
Study: NCT06388005

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: emotional freedom technique (EFT)
Description: The emotional freedom technique (EFT), founded by American scholar Gary Craig, is based on the methods of meridian science in traditional Chinese medicine (TCM) and Western psychology. Guided by the TCM theory of meridians, it quickly releases negative emotions by combining acupoint stimulation with neuro-linguistic programming, and its effectiveness has been confirmed by multiple studies.